Opaganib reduces COVID-19 mortality by 62 percent in Phase II/III study
Opaganib is the first oral pill-based therapy to significantly reduce mortality outcomes in hospitalised COVID-19 patients.
List view / Grid view
Opaganib is the first oral pill-based therapy to significantly reduce mortality outcomes in hospitalised COVID-19 patients.
The draft guidance discusses product development considerations, risk assessments and cGMPs relevant to microbiological control in non-sterile drug (NSD) manufacturing.
The EMA’s drug safety committee (PRAC) assessed risks of thrombocytopenia and venous thromboembolism with the Janssen COVID-19 Vaccine.
Crizanlizumab recommended as a treatment option for preventing recurrent sickle cell crises for people aged 16 and over in the UK.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has initiated the CVD Network to improve policies for patients.
Late-breaking data highlights the emerging clinical profile of amlitelimab in adults with inadequately controlled atopic dermatitis.
EPR's Anna Begley reviews some of the latest results for AstraZeneca’s Enhertu (trastuzumab deruxtecan) HER2-directed cancer therapy.
In a study conducted in children under 12 years old, the ganaplacide/lumefantrine combination significantly reduced malaria infection.
Phase II/III trial shows Ronapreve significantly reduced viral load in seronegative patients hospitalised with COVID-19, complimenting previous findings.
The radionuclide treatment combines radioactive iodine therapy with single-domain antibodies to target the HER2 antigen.
Interim results from the BE BRIGHT study shows that bimekizumab is effective and safe for the treatment of moderate to severe psoriasis.
Dovato demonstrated non-inferior efficacy compared to TAF-based regimens in virologically suppressed adults with HIV-1 in Phase III study.
ViroCell Biologics and Great Ormond Street Hospital (GOSH) partner to tackle the viral vector manufacturing bottleneck for clinical trials.
Innovent Biologics and AnHeart Therapeutics jointly announced the interim clinical data from a Phase II trial (TRUST) evaluating taletrectinib (AB-106), an investigational next-generation ROS1/NTRK inhibitor in ROS1-positive non-small cell lung cancer (NSCLC). The data was announced at the Chinese Society of Clinical Oncology (CSCO) 2021. Taletrectinib is an investigational next-generation…
Researchers recommend the biological safety cabinet be used whenever possible to compound parenteral products in a clinical setting.